Study to Compare Milk Protein Isolate (MPI) With Caseinate in Terms of Protein Utilization

Inclusion criteria

To be considered eligible for enrolment into the study, subjects must;

• Be able to give written informed consent.
• Be between 65 and 75 years of age.
• Be in generally good health as determined by the investigator.
• Have no evidence of gastrointestinal disease or of a functional gastrointestinal disorder as determined by the Bowel Disease Questionnaire.
• Have a stable body weight over the past 3-months.
• Have a Body Mass Index (BMI) greater than 22, for males and 20 for females and less than 30.
• Have a satisfactory nutritional status.

Exclusion criteria

Subjects will be excluded from the study if they meet any of the below criteria;

• Are less than 65 and greater than 75 years of age.
• Have evidence of gastrointestinal disease or other functional gastrointestinal disorder as determined by the Bowel Disease Questionnaire.
• Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic or any condition which contraindicates, in the investigators judgement, entry to the study).
• Having a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; to include anti-inflammatory drugs, corticosteroids, laxatives, enemas, antibiotics (within 1 month), anti-coagulants, and over-the counter non-steroidal analgesics. Subjects should have a wash-out period of two-weeks.
• Be a smoker.
• Consume more than the recommended alcohol guidelines i.e. 3-4 alcohol units a day for a man and for a woman 2-3 units a day.
• Suffer from psychiatric disease
• Prior gastrointestinal surgery (apart from appendicectomy and hernia repair) or recent unexplained bleeding.
• Have dietary habits (slimming or vegetarian diet) which could interfere with the assessment of the study product.
• Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
• Subjects may not be receiving treatment involving experimental drugs.
• If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.
• Have a malignant disease or any concomitant end-stage organ disease